Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease
Author:
- 1 May 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 36 (3) , 84-91
Abstract
Parkinson disease (PD) is a progressive, disabling, neurodegenerative disorder characterized by both motor and nonmotor symptoms. Monoamine oxidase B inhibitors, dopamine agonists, N-methyl-D-aspartate antagonists and levodopa (LD), with its various formulations and administration modes, mainly improve the motor symptoms in PD, which are thought to be related to decreased dopamine levels in the brain. Of these therapeutic drug options, LD represents the most effective and best tolerated compound when it is administered several times a day. Pharmacokinetic trials of oral LD/dopa decarboxylase inhibitor (DDCI) formulations with and without the catechol-O-methyltransferase inhibitor, entacapone, showed that repeated administration with entacapone causes an increase in both the maximum concentration (Cmax) and time to Cmax (Tmax) of LD. In addition, gastrointestinal motility may also impact plasma LD behavior. These peripheral components of LD metabolism contribute to the onset of motor complications, which are predominantly associated with LD/DDCI owing to its short plasma half-life. The increase in Tmax is related to a slower increase in plasma LD concentrations after repeated LD/DDCI intake, which may also increase the risk of wearing off. An elevation in Cmax after reiterated LD intake increases the risk of peak-dose dyskinesia. Therefore, it may be useful to start with higher doses of LD formulations in the morning and then to titrate with different LD doses during the day according to the individual patient's motor behavior, which is particularly characterized by the onset of motor complications, such as off periods and dyskinesia, in more advanced stages of PD.Keywords
This publication has 34 references indexed in Scilit:
- Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacaponeExpert Review of Neurotherapeutics, 2012
- The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrationsEuropean Journal of Clinical Pharmacology, 2011
- The Concept of Continuous Dopaminergic Stimulation: What We Should Consider when Starting Parkinson’s Disease TreatmentNeurodegenerative Diseases, 2010
- Adherence to antiparkinson medication in a multicenter European studyMovement Disorders, 2009
- COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor featuresNeuropsychiatric Disease and Treatment, 2008
- Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's diseaseParkinsonism & Related Disorders, 2007
- Levodopa, motor fluctuations and dyskinesia in Parkinson’s diseaseExpert Opinion on Pharmacotherapy, 2006
- Levodopa and the Progression of Parkinson's DiseaseNew England Journal of Medicine, 2004
- Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literatureMovement Disorders, 2001
- Quality of life in patients with Parkinson’s disease who transfer from standard levodopa to Sinemet CR: the STAR studyJournal of Neurology, 1998